Dr. Reagan @myelomatic describes BrUOG 401 study of mosunetuzumab that is currently accruing at multiple sites @BrownOncology @BrownUCancer @BrownMedicine @BrownHemOnc @Roxanne344 @lymphomatic presented at #ASH22 @DrSGraff @drdonsdizon @SenduraiMani @rwsobol @OllilaTom